siRNAs targeting ANGPTL3 for mixed dyslipidemia.

The PROLONG-ANG3 trial demonstrated that two doses of solbinsiran, an siRNA targeting hepatic ANGPTL3, given 90 days apart, decreased concentrations of apoB, triglycerides, LDL-C, non-HDL-C, ANGPTL3, and hepatic fat content at day 180 in adults with mixed dyslipidemia.1 Long-term studies assessing the safety of solbinsiran and its efficacy in decreasing the risk of atherosclerotic cardiovascular disease are warranted.